Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: a prospective single arm, open-label study

ConclusionsPatients on various solid tumour treatments achieve sero-protection rate congruent with the general population. The sero-protection HIA titres were not sustained at 24  weeks postvaccination.

Source: Supportive Care in Cancer - October 9, 2020 Category: Cancer & Oncology Source Type: research